Request to Join
has invited you to join this group
Stephanie completed her PhD in 2016 at The George Institute for Global Health, Sydney Medical School, The University of Sydney. Her thesis “Contemporary issues in the management of spinal pain” investigated the efficacy and safety of pregabalin versus placebo in reducing leg pain intensity in patients with sciatica, the increased prescription of non-first line medicines in the management of spinal pain and the role of medicines used in combination to reduce pain and disability in low back pain and sciatica. She continues to research medicine use in low back pain as a Research Fellow in the musculoskeletal division of The George Institute for Global Health investigating the overuse of analgesic medicine in low back pain within the Wiser Healthcare, a research collaboration that aims to reduce the overdiagnosis and overtreatment in healthcare.
Professor Andrew McLachlan is the Program Director of the NHMRC Centre for Research Excellence in Medicines and Ageing at the Faculty of Pharmacy, University of Sydney and at Concord Hospital’s Centre for Education and Research on Ageing. He is a pharmacist, academic and researcher experienced in clinical and experimental pharmacology and research on the quality use of medicines. His research focuses on understanding the variability in response to medicines and how this can be managed to optimise patient care, particularly in special patient populations such as older people, the very young and the critically ill. He is interested in translating clinical pharmacology research into real-world practice.
Jane is a Principal Research Fellow and Head of the Paediatric Program in the Musculoskeletal Division at The George Institute for Global Health. She is also an Professor of the Sydney Medical School at the University of Sydney. She holds an ARC Future Fellowship. Her research work has been both disciplinary and cross-disciplinary as she seeks to provide evidence to answer questions of national and international importance. She leads research in three main areas. The first and largest area is the primary care management of spinal pain, while the second and third are rapidly developing areas in paediatrics, specifically fetal alcohol spectrum disorders (FASD), and children with haemophilia. Her research focuses not only on excellence in research design but also on engaging industry, the community, state and federal governments, philanthropists and high profile global organisations in this work. She has obtained over $10.5 million in funding to support her research including funding from the NHMRC (she has obtained 9 project grants), ARC, Industry, Federal Government, NGOs and philanthropy. She is one of the most published back pain researchers in the last five years. She has published over 120 articles in international peer-reviewed journals including Lancet, JAMA and Archives of Internal Medicine. She has also contributed two books, six book chapters and Letters to the Editor. Her work has been discussed in the Federal Parliament and has informed policy development in the areas of Aboriginal health and musculoskeletal disease.
Mark Hancock is an Associate Professor of Physiotherapy, Faculty of Medicine and Health Science, Macquarie University. His research focusses on the diagnosis and management of low back pain. He has published over 100 peer reviewed papers in leading medical journals (e.g. NEJM, Lancet, and BMJ) and discipline specific journals (e.g. Spine, Physical Therapy). His work has been accompanied by editorials and received wide media attention. A/Prof Hancock is a member of the associate editorial board for the Cochrane Back Review Group and Journal of Physiotherapy board member.
Ian Harris is a practicing orthopaedic surgeon and academic. He is Professor of Orthopaedic Surgery at teh University of New South Wales (UNSW) in Sydney, Australia. His research is clinical in nature, including trials, registries, cohort studies and systematic reivews. He has published over 150 peer reviewed papers, particulalry in the field of surgical outcomes.
I am the principle investigator of 'Trial of Pregabaline for Acute and Chronic Sciatica'. My research interests are in investigating the effectiveness and cost-effectiveness of treatments for musculoskeletal conditions, to improve patient outcomes and minimise the economic burden to the individual and society. My research is supported by a fellowship from the National Health and Medical Research Council, Australia.
I have expertise is in conducting large clinical trials, systematic reviews and economic evaluation. As well as NEJM, I have published in other pretigious journals such as Lancet, JAMA and BMJ.
Richard Day is Professor of Clinical Pharmacology at University of NSW and St Vincent's Hospital Sydney, visiting Academic Fellow at Macquarie University Sydney with appointments to public and private hospitals. He has clinical practice in Clinical Pharmacology, Clinical Toxicology and Rheumatology. He has particular interests in promoting the quality of use of medicines (QUM).
Dr Day has held a number of advisory positions to the Federal Government of Australia and other organizations including; Director and Past President of the international Drug Information Association (DIA), co-chair of the Medication Safety Taskforce for the Australian Safety and Quality Council 2001-3, member of the Australian Drug Evaluation Committee 1992-97 (ADEC), inaugural Director and Management Committee member of Australian Medicines Handbook 1996-8 (AMH), chair of the Programme Committee World Conference of Clinical Pharmacology Brisbane 2004, chair of the NPS (National Prescribing Service) R&D committee (2008-10) and ex officio member Australasian Rheumatology Association Therapeutics Committee. He chairs the Medication Safety Expert Advisory Committee for the New South Wales Ministry of Health since 2010.
He was the responsible academic and Chairman (1996-2011) and is now the academic advisor to the Masters in Medical Science in Drug Development in the Department of Pharmacology, School of Medical Sciences, Faculty of Medicine at UNSW. This is a national and international distance education programme dedicated to excellence in medicines and device development world-wide.
His research focuses upon QUM and the pharmacotherapy of gout, diabetes, pain, inflammation and infectious diseases. He is also researching methods of enhancing the safe use of medicines using electronic medication management and decision support tools as one of Six Chief Investigators on a NH&MRC Programme Grant (2014-2018) and Chief Investigator on a NH&MRC Partnership Grant (2015 – 19) investigating whether feedback of serum uric acid concentrations to patients with gout via smart phones enhances adherence.